ETRA (Electra Therapeutics Inc.) stock: $7.80, $489.6M market cap, $417.6M cash, $72.0M EV, $563.2M fully diluted market cap. Next expected readout: Mar-28. Lead program: ELA026 (Secondary Hemophagocytic Lymphohistiocytosis (sHLH)), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
We are a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. Our novel approach targets signal regulatory proteins (SIRP), a family of cell surface receptors whose expression is restricted to specific immune cell populations and increases upon activation, to enable selective depletion of disease-driving cells while preserving normal immune function.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.